Literature DB >> 33547014

Esophageal cancer after sleeve gastrectomy: a population-based comparative cohort study.

Amin Andalib1, Philippe Bouchard2, Sebastian Demyttenaere2, Lorenzo E Ferri3, Olivier Court2.   

Abstract

BACKGROUND: Sleeve gastrectomy (SG) is the most common bariatric surgery; however, this approach may induce gastroesophageal reflux disease (GERD). Both obesity and GERD are independent risk factors for esophageal cancer, however the impact of SG on risk of esophageal cancer remains unknown.
OBJECTIVE: To evaluate the risk of esophageal cancer after reflux-prone bariatric surgery.
SETTING: Population-level, provincial administrative healthcare database, Quebec, Canada.
METHODS: We identified a population-based cohort of all patients with obesity who underwent reflux-prone surgery (SG and duodenal switch [DS]) or reflux-protective Roux-en-Y gastric bypass (RYGB) during 01/2006-12/2012 in Quebec, Canada. For every surgical patient, 2-3 nonsurgical controls with obesity matched for age, sex, and geography were also identified. Crude incidence rate ratios (IRRs) for esophageal cancer were calculated using person-time analysis. Hazard ratios (HRs) were obtained using multivariate cox regression.
RESULTS: A total of 4121 patients had reflux-prone procedures and 852 underwent RYGB. At a mean follow-up of 7.6 years, 8 cases of esophageal cancer were identified after bariatric surgery. Compared with RYGB, IRR for esophageal cancer in reflux-prone group was 1.45 (95%CI: .19-65.5) and HR = .83 (95%CI: .10-7.27). The crude incidence rate of esophageal cancer in the reflux-prone group was higher than that of nonsurgical controls (n = 12,159; IRR = 3.46, 95%CI: 1.00-12.5), but after adjustment the difference disappeared (HR = 2.47, 95%CI: .82-7.45).
CONCLUSIONS: Long-term incidence of esophageal cancer after reflux-prone bariatric surgery is not greater than RYGB. While crude incidence of esophageal cancer after reflux-prone surgery is higher than in nonsurgical patients with obesity, such difference disappears after accounting for confounders. Given the low incidence of esophageal cancer and slow progression of dysplastic Barrett esophagus, studies with longer follow-up are needed.
Copyright © 2020 American Society for Bariatric Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bariatric surgery; Esophageal cancer; Reflux-prone surgery; Reflux-protective surgery; Roux-en-Y gastric bypass; Sleeve gastrectomy

Year:  2020        PMID: 33547014     DOI: 10.1016/j.soard.2020.12.011

Source DB:  PubMed          Journal:  Surg Obes Relat Dis        ISSN: 1550-7289            Impact factor:   4.734


  5 in total

Review 1.  Revision Bariatric Procedures and Management of Complications from Bariatric Surgery.

Authors:  Thomas R McCarty; Nitin Kumar
Journal:  Dig Dis Sci       Date:  2022-03-26       Impact factor: 3.199

2.  Comment on: Alarmists at the Gates: Esophageal Adenocarcinoma After Sleeve Gastrectomy Is Not Different than with Other Bariatric/Metabolic Surgeries.

Authors:  Alfredo Genco; Lidia Castagneto-Gissey; Giovanni Casella
Journal:  Obes Surg       Date:  2022-08-13       Impact factor: 3.479

3.  Oesophageal and Gastric Cancer After Bariatric Surgery: an Up-to-Date Systematic Scoping Review of Literature of 324 Cases.

Authors:  Chetan Parmar; Sjaak Pouwels
Journal:  Obes Surg       Date:  2022-10-15       Impact factor: 3.479

4.  Esophageal Cancer After Bariatric Surgery: Increasing Prevalence and Treatment Strategies.

Authors:  Victor D Plat; Anne Kasteleijn; Jan Willem M Greve; Misha D P Luyer; Suzanne S Gisbertz; Ahmet Demirkiran; Freek Daams
Journal:  Obes Surg       Date:  2021-09-07       Impact factor: 3.479

5.  Serum MMP-9 and SAA in the Diagnosis of Severe Pneumonia Caused by Radiotherapy of Esophageal Cancer.

Authors:  Yu Zhou; Li Liu; Wenjun Gu
Journal:  Evid Based Complement Alternat Med       Date:  2021-08-05       Impact factor: 2.629

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.